Weight loss injection repeat prescriptions: what actually happens

Does a weight loss injection just 'auto-renew' once you're on it?

This is probably the question our prescribers hear most often from people moving across from a previous provider. The short answer is no, and that's by design. Mounjaro and Wegovy are Black Triangle medicines under additional MHRA monitoring. The clinical guidance underpinning both (NICE TA1026 for tirzepatide and NICE TA875 for semaglutide) explicitly requires ongoing review to confirm that treatment is still appropriate. Five percent weight loss after six months at the highest tolerated dose is the benchmark NICE sets for continuing; below that, the decision needs revisiting.

At a practical level, this means your repeat isn't sitting in a queue waiting to be rubber-stamped. A named prescriber reads your update. They look at how you've responded, whether side effects are manageable, whether your dose should stay the same or move up, and whether anything in your health picture has changed. That clinical scrutiny is what makes ongoing treatment both legal and safe. Read about how Mounjaro works as a weight loss injection for more on the titration process.

There's also a patient-safety dimension that goes beyond the paperwork. If you want to understand what a weight loss injection involves before committing to treatment, that's worth reading through before your first consultation. GLP-1 medicines slow gastric emptying and reduce appetite significantly, your nutritional needs, your other medicines and your tolerance can all shift over months of treatment. A perfunctory repeat process misses that. Worth knowing before you assume one provider's approach is the same as another's.

What does the review actually check before a repeat is issued?

Each review at nume looks at several things. Your current dose, the pen you're using, any side effects since the last supply, and whether your weight response is in line with what the clinical evidence shows. For a dose increase, the prescriber needs evidence that you're established at your current dose, not just that you've had the pen in the fridge. Transfer patients are asked to provide details of their current treatment so the prescriber can see the full picture, rather than starting blind.

The MHRA's January 2026 Drug Safety Update on GLP-1 medicines flagged acute pancreatitis as an infrequent but serious risk: severe, persistent stomach pain that may radiate to the back is a reason to get urgent medical help and to flag it with your prescriber before any repeat is issued. That kind of clinical checkpoint only works if someone is actually reading your notes. See what a fully reviewed private prescription includes on cost if you're comparing providers.

The injection itself, once approved and dispatched, arrives via DPD the next working day in plain, unbranded packaging, you'll get a tracking link so you know exactly when to expect it. The pen is pre-filled and ready to use once you've read the patient information leaflet your prescriber's instructions are based on.

How does the repeat process differ on the NHS versus private?

On the NHS, tirzepatide through primary care (from April 2026, where GP practices have opted in) and Wegovy through specialist weight management services both sit inside structures that include regular monitoring appointments. The NHS England guidance on weight management injections is clear that ongoing supply depends on continued participation in wrap-around dietary and activity support, not just the prescription itself.

Private providers vary. Some use a questionnaire that feeds into a system with minimal human review. At nume, the approach is that a GPhC-registered Independent Prescriber personally reviews every repeat, the same standard applies to your first order and your tenth. There are no subscriptions and no auto-renewals; each repeat is a discrete clinical decision. You can verify any online pharmacy, including ours (GPhC registration 9012878), at the GPhC pharmacy register. That transparency matters when you're trusting a service with an ongoing prescription.

If you're considering the private route, understanding what private weight loss by injection involves before your first consultation will help you ask the right questions. And if you've heard there are supply issues with certain pens at the moment, the current injection shortage picture is covered separately.

What should you do if your repeat is delayed or you need clinical advice between orders?

Supply delays do happen, pen availability has fluctuated across both Mounjaro and Wegovy throughout 2024 and 2025. If your repeat is delayed, the first thing to do is contact your provider's clinical team rather than seek supply elsewhere. Taking a pen from a different dose, switching products informally, or sourcing injections from an unverified seller without a prescription each carry real risks. The MHRA has warned publicly about counterfeit weight loss pens containing incorrect substances, including insulin, seized in large volumes across the UK.

Between orders, if you have a side effect question, a concern about how you're responding, or anything that feels medically relevant, that's exactly what aftercare is for. At nume, our prescribers are reachable seven days a week. The FAQs cover the most common between-order questions, or you can get in touch with the clinical team directly. For a broader look at the treatment options available, our treatment overview sets out what's currently licensed in the UK.

If you haven't started yet and want to understand whether you'd be suitable, starting a free consultation is the most direct route to an answer from a prescriber rather than a checklist.